Natrol S&E
This article was originally published in The Tan Sheet
Executive Summary
Revenues during the firm's second quarter grew 17.8 % to $19.5 mil., fueled by the strong performance of new the products which more than offset a decline from the discontinuation of Ester-C, the Chatsworth, Calif.-based firm says. The nutritional products company adds it is well-positioned to enter the international marketplace, and is benefiting from the diversification of its business through the recent acquisition of MRI (1"The Tan Sheet" June 18, 2007, p. 7). Operating income jumped 172.9% during the quarter to $737,000 while net income was $4.2 mil. compared to $100,000 in the year-ago period, the firm notes...
You may also be interested in...
Natrol Pumps Up In Sports Nutrition Market With MRI Acquisition
Dietary supplement manufacturer Natrol expands its sports nutrition product offerings with its $8 million cash acquisition of Medical Research Institute
Joint Mission: FDA And VA Partner On Device Development Initiative
The US Food and Drug Administration and the Veterans Health Administration are partnering to create tools that can help novel technology reach patients more quickly and easily.
Gamida Set For Breakthrough Transplant Therapy Approval – But Cash Problems Could Hit Launch
With a new CEO at the helm, Gamida is closing in on an FDA approval, but a lack of cash could hobble its US launch efforts for allogeneic cell therapy product omidubicel.